NEXGEL (NXGL) Competitors

Hyperfine (NASDAQ:HYPR) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.

Is HYPR or NXGL more profitable?

NEXGEL has a net margin of -52.60% compared to Hyperfine's net margin of -309.42%. Hyperfine's return on equity of -57.54% beat NEXGEL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-309.42%	-57.54%	-50.38%
NEXGEL	-52.60%	-71.19%	-34.79%

Does the MarketBeat Community prefer HYPR or NXGL?

Hyperfine received 7 more outperform votes than NEXGEL when rated by MarketBeat users.

Company	Underperform	Outperform
Hyperfine	Outperform Votes 8 50.00%	Underperform Votes 8 50.00%
NEXGEL	Outperform Votes 1 50.00%	Underperform Votes 1 50.00%

Which has more volatility and risk, HYPR or NXGL?

Hyperfine has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Do insiders & institutionals believe in HYPR or NXGL?

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 2.2% of NEXGEL shares are held by institutional investors. 31.0% of Hyperfine shares are held by insiders. Comparatively, 20.5% of NEXGEL shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has stronger earnings & valuation, HYPR or NXGL?

NEXGEL has lower revenue, but higher earnings than Hyperfine. NEXGEL is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.73M	5.53	-$44.24M	-$0.54	-1.54
NEXGEL	$10.23M	1.79	-$3.16M	-$0.45	-5.31

Do analysts prefer HYPR or NXGL?

Hyperfine presently has a consensus target price of $1.06, indicating a potential upside of 27.11%. Given Hyperfine's stronger consensus rating and higher probable upside, research analysts plainly believe Hyperfine is more favorable than NEXGEL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NEXGEL	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media favor HYPR or NXGL?

In the previous week, Hyperfine and Hyperfine both had 4 articles in the media. Hyperfine's average media sentiment score of 1.38 beat NEXGEL's score of -0.28 indicating that Hyperfine is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperfine	Positive
NEXGEL	Neutral

Summary

Hyperfine beats NEXGEL on 12 of the 16 factors compared between the two stocks.